Graziana Colaianni1, Maria F Faienza2, Lorenzo Sanesi1,3, Giacomina Brunetti4, Patrizia Pignataro1, Luciana Lippo1, Sara Bortolotti1, Giuseppina Storlino1, Laura Piacente2, Gabriele D'Amato5, Silvia Colucci4, Maria Grano6. 1. Department of Emergency and Organ Transplantation, School of Medicine-University of Bari, Bari, Italy. 2. Paediatric Unit, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy. 3. PhD School in "Tissue and Organ Transplantation and Cellular Therapies", Department of Emergency and Organ Transplantation, School of Medicine-University of Bari, Bari, Italy. 4. Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Human Anatomy and Histology, School of Medicine-University of Bari, Bari, Italy. 5. Neonatal Intensive Care Unit, Di Venere Hospital, Bari, Italy. 6. Department of Emergency and Organ Transplantation, School of Medicine-University of Bari, Bari, Italy. maria.grano@uniba.it.
Abstract
BACKGROUND: Irisin is a myokine secreted by skeletal muscle during physical activity. Irisin treatment increased cortical bone mineral density (BMD) in young healthy mice and restored bone and muscle mass loss in a mouse model of disuse-induced osteoporosis and muscular atrophy. In humans, Irisin was positively correlated with BMD in young athletes. Considering that the bone mass reached during childhood is one of the most important determinants of lifelong skeletal health, we sought to determine if Irisin levels were correlated with bone mineral status in children. METHODS: Irisin and bone metabolic markers were quantified in sera and bone mineral status was evaluated by quantitative ultrasound in a population of 34 healthy children (9.82 ± 3.2 years). RESULTS: We found that Irisin levels were positively correlated with the amplitude-dependent speed of sound Z-score (r = 0.305; p < 0.001), bone transmission time Z-score (r = 0.375; p < 0.001) and osteocalcin (r = 0.370; p < 0.001), and negatively with Dickkopf WNT Signaling Pathway Inhibitor 1 (r = -0.274; p < 0.001). CONCLUSION: In a regression analysis model, Irisin was one of the determinants of bone mineral status to a greater extent than bone alkaline phosphatase and parathyroid hormone, indicating that Irisin might be considered as one of the bone formation markers during childhood.
BACKGROUND: Irisin is a myokine secreted by skeletal muscle during physical activity. Irisin treatment increased cortical bone mineral density (BMD) in young healthy mice and restored bone and muscle mass loss in a mouse model of disuse-induced osteoporosis and muscular atrophy. In humans, Irisin was positively correlated with BMD in young athletes. Considering that the bone mass reached during childhood is one of the most important determinants of lifelong skeletal health, we sought to determine if Irisin levels were correlated with bone mineral status in children. METHODS: Irisin and bone metabolic markers were quantified in sera and bone mineral status was evaluated by quantitative ultrasound in a population of 34 healthy children (9.82 ± 3.2 years). RESULTS: We found that Irisin levels were positively correlated with the amplitude-dependent speed of sound Z-score (r = 0.305; p < 0.001), bone transmission time Z-score (r = 0.375; p < 0.001) and osteocalcin (r = 0.370; p < 0.001), and negatively with Dickkopf WNT Signaling Pathway Inhibitor 1 (r = -0.274; p < 0.001). CONCLUSION: In a regression analysis model, Irisin was one of the determinants of bone mineral status to a greater extent than bone alkaline phosphatase and parathyroid hormone, indicating that Irisin might be considered as one of the bone formation markers during childhood.
Authors: G Colaianni; A Notarnicola; S Colucci; M Grano; L Sanesi; G Brunetti; L Lippo; M Celi; L Moretti; V Pesce; G Vicenti; B Moretti Journal: J Biol Regul Homeost Agents Date: 2017 Oct-Dec, Impact factor: 1.711
Authors: M F Faienza; G Brunetti; G Grugni; D Fintini; A Convertino; P Pignataro; A Crinò; S Colucci; M Grano Journal: J Endocrinol Invest Date: 2021-03-03 Impact factor: 5.467
Authors: Maria Felicia Faienza; Giuseppe Lassandro; Mariangela Chiarito; Federica Valente; Loredana Ciaccia; Paola Giordano Journal: Int J Environ Res Public Health Date: 2020-03-13 Impact factor: 3.390
Authors: A Gaudio; R Rapisarda; A Xourafa; L Zanoli; V Manfrè; A Catalano; S S Signorelli; P Castellino Journal: J Endocrinol Invest Date: 2021-03-06 Impact factor: 5.467